ELI LILLY & Co
NYSE: LLY·Indianapolis, Indiana·CIK 0000059478
- Price
- $1,431.67
- Base IV
- $655.22
Valuation snapshot
At $1,431.67, the price is above even our bull case of $1,277.07.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $655.22
- 46% of the price · range $247.46–$1,277.07
- Price vs base case
- 119% above
- $1,431.67 against $655.22
- Base case · our researched forecast, 2026-10-30See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has risen 4.2% since this valuation was struck on 2026-10-30, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $247.46 to bull $1,277.07. Values per share.
Price against each value
- Bear case
- $247.46
- Price 479% above
- No growth
- …
- —
- Base case
- $655.22
- Price 119% above
What does Eli Lilly & do?
Eli Lilly makes prescription medicines that doctors use to treat diabetes, obesity, cancer, Alzheimer's disease, and autoimmune conditions, helping patients control blood sugar and weight and slow disease progression.
It brought in $86.5B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Indianapolis, Indiana
- Trades on
- NYSE as LLY
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 32¢ was left as profit after every cost, interest and tax. The biggest cost is research and development, 18¢ of every dollar.
- Making what it sells16¢
- Research and development18¢
- Sales, marketing and admin15¢
- Everything else, including interest11¢
- Tax8¢
- Left as profit32¢
Who pays Eli Lilly &, and for what?
Eli Lilly discovers, makes and sells prescription medicines in about 90 countries. Most of its money comes from diabetes and weight-loss drugs, mainly Mounjaro and Zepbound. It also sells medicines for cancer, immune conditions such as psoriasis and eczema, migraine and Alzheimer's disease.
In the U.S. most of its medicines are sold through three large drug wholesalers (McKesson, Cencora and Cardinal Health), and the cost is mostly paid by insurers, employers, government health programs such as Medicare and Medicaid, and more and more by patients buying directly through its LillyDirect service.
Mounjaro
35%A weekly injection that treats type 2 diabetes by helping control blood sugar. It was Lilly's biggest product in 2025, with about $23.0 billion in sales.
Zepbound
21%The same medicine as Mounjaro (tirzepatide), approved for weight loss. Almost all of its 2025 sales of about $13.5 billion were in the U.S.
Verzenio
9%A pill for certain types of breast cancer. It made about $5.7 billion in 2025 and was Lilly's largest cancer medicine.
Other products (including Trulicity, Taltz and Jardiance)
35%Everything else, about $22.9 billion in 2025. This includes the diabetes drugs Trulicity and Jardiance (sold with Boehringer Ingelheim), the psoriasis drug Taltz, insulins such as Humalog, and newer medicines such as Kisunla for Alzheimer's.
Eli Lilly’s Trulicity 3 mg single-dose injection penRaimond Spekking, CC BY-SA 4.0, via Wikimedia Commons
Where its work physically happens, beyond headquarters:
- Lilly Lebanon Campus — Lebanon, United States. Lilly's cornerstone domestic manufacturing campus includes its future largest U.S. API plant for Zepbound, Mounjaro, Foundayo and retatrutide, plus its first dedicated genetic-medicine manufacturing facility.
- Generation Park API Facility — Houston, United States. The planned $6.5 billion facility will manufacture small-molecule APIs, including Foundayo (orforglipron), at scale for Lilly's cardiometabolic and broader pipeline.
- Greenbrier South API Facility — Huntsville, United States. This planned $6 billion API facility will add domestic capacity for synthetic and peptide medicines, including Foundayo (orforglipron).
- Goochland County Bioconjugate Facility — Richmond, United States. The planned $5 billion facility will be Lilly's first fully integrated API and drug-product site dedicated to bioconjugates, monoclonal antibodies and antibody-drug conjugates.
- Kenosha County Manufacturing Site — Pleasant Prairie, United States. Lilly's $4 billion acquisition and expansion program is adding injectable-medicine production, device assembly and packaging capacity for diabetes, obesity and pipeline products.
How is the business doing?
Sales grew from $24.5B in 2020 to $65.2B in 2025, about 22% a year.
What does management say it's aiming for?
Lilly says it exists to combine care for patients with scientific discovery to create medicines that improve people's lives around the world.
“Our purpose is to unite caring with discovery to create medicines that make life better for people around the world.”
What management says it is working on now:
Getting weight-loss medicines to more people
Lilly is working to widen access to Zepbound and its new weight-loss pill Foundayo. This includes Medicare coverage for weight management, which Lilly says now covers millions of Americans, and selling directly to patients through LillyDirect.
Lilly Q2 2026 earnings release (Form 8-K)Launching Foundayo, its weight-loss pill
Foundayo (orforglipron) is a daily pill version of this type of medicine. It was approved in the U.S. in April 2026 and brought in $98 million in its first reported quarter. Lilly has also asked the FDA to approve it for type 2 diabetes.
Lilly Q2 2026 earnings release (Form 8-K)Moving retatrutide toward approval
Lilly says three more late-stage trials of retatrutide, its next-generation obesity drug, were positive. It has the data it needs to apply for approval in obesity, sleep apnea and knee arthritis pain.
Lilly Q2 2026 earnings release (Form 8-K)Building more factories
Lilly committed another $4.5 billion to expand its Indiana manufacturing sites and opened its first dedicated genetic medicine plant. Its spending on property and equipment rose to $5.3 billion in the first half of 2026, from $3.2 billion a year earlier.
Lilly Q2 2026 earnings release (Form 8-K)Buying companies to add future medicines
In the first half of 2026 Lilly bought several biotech companies, including Ventyx, Orna, Ajax, Centessa and Kelonia. In July it agreed to buy three infectious-disease companies for up to $3.9 billion.
Eli Lilly 10-Q for the quarter ended June 30, 2026
- Revenue, Full year 2026
- $85.0 billion to $87.0 billion (raised from $82–85 billion)
- Lilly Q2 2026 earnings release (Form 8-K)
- Earnings per share (non-GAAP, the company's adjusted measure), Full year 2026
- $35.50 to $36.50
- Lilly Q2 2026 earnings release (Form 8-K)
- Performance margin (Lilly's own profit-margin measure), Full year 2026
- 49.0% to 50.5%
- Lilly Q2 2026 earnings release (Form 8-K)
What's changing right now?
Growth is slowing. In Q3 2026 it sold 39% more than a year earlier. The year before, quarters averaged 50%.
Since Jul 2026 the share price has risen 24%, from $1,154.97 to $1,431.67.
Recently
October 29, 2026
Nine-month property and equipment purchases changed to $8.4B
Lilly Q3 2026 Form 10-Q, nine-month 2026 figureOctober 29, 2026
Quarterly gross margin changed to 83.9%
Lilly Q3 2026 resultsOctober 29, 2026
Mounjaro quarterly sales changed to $10.7B
Lilly Q3 2026 results
Coming up
FDA review under way after the 2026 submission
FDA decision on Foundayo for type 2 diabetes
Lilly has asked the FDA to approve its weight-loss pill Foundayo for type 2 diabetes too, after three late-stage trials showed better blood-sugar control and weight loss. Approval would let the pill reach more patients.
Lilly Q2 2026 earnings release (Form 8-K)Q1 2027 (planned submission)
Retatrutide approval application
Lilly plans to ask the FDA to approve retatrutide, a next-generation obesity drug, using trial data in obesity, sleep apnea and knee arthritis pain.
Lilly Q2 2026 earnings release (Form 8-K)2027 (lawsuits starting in 2026)
Mounjaro/Zepbound data protection ends in the U.S.
U.S. data protection for tirzepatide, the ingredient in Mounjaro and Zepbound, ends in 2027, though its main patent runs to 2036. Generic makers have already filed to sell copies, and Lilly plans to sue to block them.
Eli Lilly 10-Q for the quarter ended June 30, 20262028
Government-set Medicare prices for Trulicity and Verzenio
After Jardiance's government-set Medicare price began in 2026, Trulicity and Verzenio are scheduled to get government-set Medicare prices too. Lilly expects more of its products to be selected later.
Eli Lilly 10-K for fiscal year 2025, Item 1A Risk Factors
Our own estimate moved too: the base case went from $597.60 to $655.22 a share between our last two valuations. The biggest reason: Quarterly gross margin moved from an unreported prior value to 83.9%, as reported in Lilly Q3 2026 results.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Heavy reliance on one medicine
Mounjaro and Zepbound, which share one active ingredient, made up 56% of 2025 revenue. Any problem with these drugs, such as new competitors, safety concerns or lower prices, would hit the whole company hard.
From the company's own filingsWould hit how fast sales growEli Lilly 10-K for fiscal year 2025, Item 1A Risk Factors
Government and insurer pressure on prices
Medicare now sets prices for some drugs. Jardiance's 2026 Medicare price is 66% below its 2023 list price, and Trulicity and Verzenio follow in 2028. Lilly also has a voluntary pricing agreement with the U.S. government, and many insurers do not cover weight-loss drugs.
From the company's own filingsWould hit how fast sales growEli Lilly 10-K for fiscal year 2025, Item 1A Risk Factors
Patent expirations and generic challenges
When patents run out, cheaper copies usually cut sales quickly. In July 2026 several companies told Lilly they plan to sell generic Mounjaro or Zepbound, and Lilly plans to sue. Trulicity loses key protection around 2027.
From the company's own filingsWould hit how fast sales growEli Lilly 10-Q for the quarter ended June 30, 2026
Compounded and fake copies
Lilly warns that fake versions and copies made in bulk by compounding pharmacies can take sales, push prices down, harm patients and confuse them about its brands.
From the company's own filingsWould hit how fast sales growEli Lilly 10-K for fiscal year 2025, Item 1A Risk Factors
Manufacturing and supply problems
Lilly depends on complex factories, outside suppliers (some based in China) and contract manufacturers. Disruptions, quality problems or tariffs could cause shortages and raise costs.
From the company's own filingsWould hit how much of each sale it keepsEli Lilly 10-K for fiscal year 2025, Item 1A Risk Factors
Costly research and acquisitions may not pay off
Most drug candidates fail. Lilly is spending heavily on research, factories and buying other companies; in Q2 2026 alone it took $2.8 billion in charges for acquired research projects. If these bets fail, the money is lost.
From the company's own filingsWould hit how much it has to reinvestEli Lilly 10-Q for the quarter ended June 30, 2026
Q3 worldwide realized prices fell 0.15 despite a 0.53 increase in volume.
From our researchWould hit how fast sales growLilly Q3 2026 results
Nine-month operating cash flow reached $27.420 billion, more than twice the prior-year figure.
From our researchWould hit how much it has to reinvestLilly Q3 2026 Form 10-Q
Is it a good business?
From 2016 to 2025 it earned between -2% and 319% on its shareholders' equity, a median of 60%.
The number of shares has held roughly steady over the past year.
It owes $44.6B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $1,431.67. Our put its value between $247.46 and $1,277.07, with $655.22 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $247.46
After several years of rapid sales growth, Lilly keeps growing, but lower medicine prices and heavier spending take much of the benefit.
Base case, $655.22
Lilly's recent surge in sales continues at a slower pace, while growing demand for its medicines largely offsets lower prices and expansion costs.
Bull case, $1,277.07
Lilly builds on its recent surge in sales as demand for its leading and newer medicines stays strong and each sale brings in more profit.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 119%
For Eli Lilly & to be worth today's $1,431.67, sales would need to grow about 37.2% a year. We assume 17.2%. Over the last 5 years, sales grew 25.5% a year.
Or, if sales grow 17.2% as we assume, the price works with a profit margin of 77.7% (we assume 37.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 37.2% a year?
Try your own numbersWe're not very sure of this range: it scores 46 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $655.22 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average17.2%
Next year 28.0%, then about 15%
- Operating margin37.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$655.22 -54.2%
